Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nichiiko Sanofi Japan Gets Permission From Sanofi To Sell Anti-Allergy Allegra Generic From June

This article was originally published in PharmAsia News

Executive Summary

Nichiiko’s and Sanofi’s joint venture company Nichiiko Sanofi Aventis was given permission to exclusively produce and market SANIK, the generic version of Sanofi’s anti-allergy drug Allegra (fexofenadine hydrochloride) on April 16.

You may also be interested in...



Mallinckrodt’s Terlipressin Narrowly Clears US FDA Panel As Need For Liver Treatment Outweighs Safety Worries

Advisory committee votes 8-7 to recommend approval for terlipressin to treat HRS-1 but is critical of Mallinckrodt’s plan to mitigate the risk of respiratory failure.

ECHA Committee Stops Short Of Advising Derogation Or Deadline Extension For Cosmetic Microplastic Ban

Uncertainties related to leave-on cosmetics’ microplastic releases to the environment, and the costs industry would face in removing microplastic from such products, “do not allow for SEAC to conclude whether other options would be more appropriate than a ban,” the European Chemicals Agency’s Socio-Economic Analysis Committee says in a 1 July draft opinion.

Orphan Exclusivity: Rarely Used, But Well-Known, Loophole Would Be Closed By House Legislation

US FDA could revoke orphan designation or exclusivity if cost recovery requirements were not satisfied under bill unanimously passed by the House Energy and Commerce Committee.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1126271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel